High Resolution Mass Spectrometer

The contract is for a high-resolution mass spectrometer designed to meet the demanding requirements of genotoxic impurity testing and impurity profiling in complex drug products, including peptides and proteins. This instrument delivers the high sensitivity and resolution necessary to accurately characterize trace impurities and structural variants in advanced therapeutics, directly supporting the FDA’s mission to ensure the quality and safety of an increasingly complex U.S. drug supply. It is built for high-throughput analysis, enabling efficient processing of large sample volumes critical for regulatory decision-making. The system includes updated software capable of processing mass spectrometry data for biopharmaceutical characterization, with a key enhancement being a new module for oligonucleotide data analysis that significantly expands the agency’s analytical capabilities for these emerging drug modalities. The instrument will serve as a core asset for the GDUFA and OMUFA user fee programs, providing the robust, reliable data needed to evaluate generic and complex drug products. It will be deployed in FDA laboratories to strengthen surveillance and quality assessment of cutting-edge therapeutics entering the market.